Continue to Site

FDA clears antibiotic-embedded hernia mesh for fighting implant infections

By Jim Hammerand | April 6, 2022

Ariste Medical’s polypropylene hernia mesh [Image courtesy of Ariste Medical]

Ariste Medical recently won FDA 510(k) clearance for its drug-embedded, polypropylene hernia mesh to fight microbial colonization.

The Salt Lake City-based drug-device developer said the patents and proprietary formulations behind the technology could prevent infection, inflammation or clotting associated with implants.

Ariste’s synthetic mesh carries two antibiotics — minocycline and rifampin — to prevent contamination by MRSA, E. coli and other bacterial pathogens associated with surgical site infections. The proprietary formulation can be applied to a variety of medical devices and incorporate any drug to address infection, restenosis, thrombosis and inflammation, the company said.

Get the full story at our sister site, Medical Design & Outsourcing.

About The Author

Jim Hammerand

Jim Hammerand is the managing editor of Medical Design & Outsourcing. He has more than 15 years of professional journalism experience spanning newspapers, magazines, websites and broadcast news. For nearly a decade, he reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then managing editor of the Puget Sound Business Journal in Seattle. He holds a bachelor’s degree in journalism from the University of Minnesota. He is based near Seattle in Edmonds, Washington, where he and his family live. Connect with him on LinkedIn or by email at jimhammerand@wtwhmedia.com.